MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3
Status:
Completed
Trial end date:
2020-02-06
Target enrollment:
Participant gender:
Summary
To assess the degree of systemic exposure of S6G5T-3 compared to the Reference Listed Drug
(RLD) Retin-A® 0.1% Cream when applied topically once daily for 14 days, under maximal use
conditions in adolescents ≥12 years of age and adults with acne vulgaris.